Compounded tirzepatide is a prescription formulation prepared by a compounding pharmacy for an identified patient. It can be lawfully dispensed when the prescription and pharmacy meet federal and state compounding requirements, but it is not a generic version of Mounjaro or Zepbound. That distinction matters: a compounded preparation is different from an FDA-approved product, and the formulation offered here is not FDA-approved. The national shortage that once allowed broader compounding is over, so the patient-specific reason now matters.
What compounded tirzepatide actually is
Traditional compounding is the preparation of a medication to meet an individual patient's clinical need. One familiar example is removing an inactive ingredient that causes an allergy. For tirzepatide, a licensed pharmacist in a state-licensed pharmacy may work under section 503A of the Federal Food, Drug, and Cosmetic Act when the statutory conditions are met. The medication is made after receipt of a prescription for that patient.
That route is different from manufacturing an approved brand or generic. The FDA's compounding overview says state boards of pharmacy generally handle day-to-day oversight of 503A pharmacies, while FDA conducts surveillance and for-cause inspections. The finished compounded preparation does not go through the agency's premarket review.
| Question | Mounjaro or Zepbound | Patient-specific 503A formulation |
|---|---|---|
| Regulatory route | New Drug Application reviewed by FDA | Federal compounding exemptions, if every condition is met |
| Intended use | Mounjaro for type 2 diabetes; Zepbound for chronic weight management and certain adults with obesity and sleep apnea | The individual need documented by the prescriber |
| Product review | Exact product, labeling and manufacturing process reviewed before marketing | No FDA premarket review of the finished preparation |
| Dispensing | Prescription product in manufacturer-set presentations | Prescription filled for an identified patient by a state-licensed pharmacy |
| Generic status | Brand products | Not a generic and not interchangeable by approval |
FDA's records describe Mounjaro's type 2 diabetes indication and Zepbound's chronic weight-management indication. Those labels do not transfer to a pharmacy's compounded preparation.
Is compounded tirzepatide legal after the shortage?
Yes, in limited patient-specific circumstances. Shortage status is no longer the broad basis for making copies of tirzepatide injections. FDA first determined the shortage was resolved on October 2, 2024, reconsidered the record, and confirmed that determination on December 19, 2024. After a federal court denied a preliminary injunction on March 5, 2025, shortage-related enforcement discretion ended for 503A compounders; the corresponding 503B period ended March 19, 2025.
As of August 2026, FDA's current GLP-1 compounding policy states that tirzepatide is neither on the drug-shortage list nor the 503B bulks list. For 503A pharmacies, the policy has two important parts:
- The medication must be compounded for an identified patient on receipt of a prescription.
- A compounder may not make, regularly or in inordinate amounts, a product that is essentially a copy of one commercially available. An exception can apply when the prescriber determines and documents that a change produces a significant difference for that patient.
This is narrower than saying any prescription makes any tirzepatide compound permissible. It also means a national supply headline cannot decide whether compounding is appropriate for one person. A licensed provider may prescribe a patient-specific formulation within the applicable rules; that decision belongs in the patient-doctor relationship.
What “not FDA-approved” means here
It means FDA has not evaluated that finished formulation for safety, effectiveness, quality, therapeutic equivalence or its specific manufacturing process before marketing. It does not mean that pharmacy compounding has no legal framework. It does mean the evidence for a branded product cannot simply be pasted onto every compounded vial.
The distinction is visible in the trials. In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes were randomized for 72 weeks. Mean weight change was −15.0%, −19.5% and −20.9% in the three tirzepatide groups, versus −3.1% with placebo (Jastreboff et al., NEJM 2022). In SURPASS-2, 1,879 adults with type 2 diabetes were randomized for 40 weeks; mean HbA1c changes were −2.01, −2.24 and −2.30 percentage points across the tirzepatide groups, versus −1.86 with semaglutide 1 mg (Frías et al., NEJM 2021).
Those are trial results for the products and protocols studied. They are not formulation-specific results for Promise's compounded medication, and they do not establish that two preparations from different sources are equivalent. For the clinical context around adverse effects, see tirzepatide side effects.
Prescribed medication versus a grey-market vial
“Compounded” should describe how a pharmacy prepared a prescription medication. It should not be a loose synonym for any vial offered online.
| Check | Prescribed compounded route | Grey-market online vial |
|---|---|---|
| Clinical review | Licensed provider reviews history and medications | No accountable prescriber |
| Prescription | Issued for the patient when appropriate | Often absent |
| Source | Identified, state-licensed pharmacy | Seller or source may be unclear |
| Label | Patient, pharmacy, concentration and directions are traceable | Identity or contents may be difficult to verify |
| Follow-up | Provider and pharmacy can answer questions | Often no clinical relationship |
FDA has documented products falsely labeled as compounded tirzepatide, including labels naming pharmacies that did not make them. Its GLP-1 safety update also says the agency had received more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026. That number is not a count of proven causal events: FDA says it cannot always determine whether the product caused a report, and federal reporting is not mandatory for state-licensed pharmacies that are not outsourcing facilities.
How the prescribed route works at Promise
The route starts with a tirzepatide-specific medical intake, not a checkout page for a vial. A licensed provider in Promise's prescriber network reviews every request, including medical history, current medication and the reason a compounded formulation is being considered. The provider prescribes or declines on medical eligibility, and not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses it; the prescriber sets the dose and the pharmacy supplies the instructions for that exact concentration.
That clinical chain is what separates telehealth prescribing from an anonymous online transaction. How compounded medications are made explains the pharmacy workflow, while the tirzepatide product page describes Promise's intake path.
What to verify before a vial ships
A credible route should be able to identify the reviewing provider and dispensing pharmacy, explain why a compounded preparation fits the individual request, and provide the exact concentration, ingredients, storage conditions and measurement instructions. The label should match the pharmacy that actually prepared the medication. Follow-up should remain available after dispensing.
The cleanest question is not whether a website uses the word “compounded.” It is whether an accountable prescriber documented a patient-specific decision and an identifiable licensed pharmacy filled that prescription under the rules in effect now.